
Annual Report

2011/12



Chairman's Report

2011/12 has been a year of significant progress for the Cure4CF Foundation (Cure4CF), delivering its largest profit to date. For the first time, Cure4CF was able to provide grants of more than \$100,000 to the Adelaide Cystic Fibrosis Gene Therapy Research Group at the Women's and Children's Hospital in Adelaide, South Australia.



Two major milestones occurred throughout the year: the opening of the Allan Scott CF Research Laboratory in April, and the signing of a formal service agreement with the Women's and Children's Health Network (WCHN). These developments have significantly increased the capacity of Cure4CF to meet its goal of finding a cure for Cystic Fibrosis Airway Disease. Throughout this process Cure4CF has remained true to its core values of being a highly cost effective charity. In 2011/2012 Cure4CF returned a cost of fundraising of only 4 cents in the dollar – an extraordinarily efficient outcome. Both achievements were only possible through the hard work and dedication of board members, volunteers and of course, our wonderful supporters.

Allan Scott CF Research Laboratory

On 12 April 2012 the Honourable Tanya Plibersek MP, Federal Minister for Health and the Honourable John Hill, SA Minister for Health and Ageing, formally opened the Allan Scott CF Research Laboratory. This long anticipated state-of-the-art facility provides the Adelaide Cystic Fibrosis Gene Therapy Research Group with an enhanced and dedicated capability to undertake research that was not previously possible. The construction and development of the laboratory was a key objective of Cure4CF and has been the focus of fundraising endeavours for almost ten years.

Cure4CF thanks the WCHN for their development of this facility, the WCH Foundation for their substantial funding commitment and the late Allan Scott OAM and the Scott family for their generous and ongoing support of the project.

WCHN Service Agreement

In July 2012 Cure4CF reached agreement with the WCHN for base funding support of the Adelaide Cystic Fibrosis Gene Therapy Research Group. This was formalised in the signing of a service agreement between the two parties.

This significant development further enhances the stakeholder status Cure4CF has with the WCHN and crucially, ensures regular and open communication regarding the progress and requirements of the research group. This allows Cure4CF to approach the South Australian and Australian

community for funds in a much more confident and expedient manner than it has been able to in the past.

Cure4CF expresses its sincere thanks to Gail Mondy, Chief Executive of the WCHN, Phil Robinson, Executive Director of Corporate Services and Dr Andrea Averis, Director of the Research Secretariat for their willingness to engage so openly with Cure4CF.

Fundraising

Cure4CF had its most successful year in 2011/12, delivering its largest profit of \$127,107 while continuing to be true to its founding objective of being a low cost charity. As our financial statements demonstrate, the cost of fundraising in 2011/12 was a low 4.0¢. This is again largely due to the volunteer nature of the organisation in which directors have made substantial contributions of time to deliver fundraising objectives. Cure4CF will continue to implement fundraising initiatives, especially through the use of social media, that maximise the value of all donations. Investment in a professional grants writer in 2010/2011 also bore fruit in this financial year. Variety – the children's charity provided a grant of more than \$90,000 to purchase a state-of-the-art ultracentrifuge, a crucial piece of laboratory equipment. Cure4CF is sincerely grateful for the outstanding generosity of Variety. AHA(SA) also supported equipment in the Allan Scott CF Research Laboratory through a grant of almost \$20,000, while Australian Executor Trustees, through their discretionary trust, have again supported the research project through a donation of \$10,000. Our sincere thanks to these two organisations.

Once again, Cure4CF has enjoyed wonderful support from Penfolds Wines, Amcor and Collotype Labels, who come together to produce the annual release of the Climbing Rose Shiraz Cabernet and Riesling.

Cure4CF Foundation would like to especially recognise Danika Rhodes and Amanda Kenny who both organised successful City-to-Bay Fun Run teams in 2011. The efforts of these two women in mobilising their families, friends and colleagues saw more than \$3,000 raised for Cure4CF. Also deserving of recognition is Monica Briffa who has initiated an ongoing series of fundraising activities throughout her community network which is successful in delivering a regular flow of funds to Cure4CF. To these women and their supporters we thank you for your continued support of the Cure4CF Foundation. We encourage other members of the CF community to emulate their lead as it is supporters such as these who can make a quick and significant impact upon the resources we are able to provide.

On behalf of the Board of the Cure4CF I would like to thank all of the people and organisations in our donor list for their support in 2011/12 and look forward to your support in the next year.

Funding Support

During the year, Cure4CF was able to use the proceeds of fundraising activities to support the Adelaide Cystic Fibrosis Gene Therapy Research Group through a range of grants totalling more than \$100,000. These grants enabled equipment purchases and supported team members with conference attendance and travel and other professional development opportunities. Importantly, Cure4CF continued to cover costs for the employment of an Office Manager for the group on a 0.4FTE (full-time equivalent) basis, enabling the research scientists to be divested of a range of administrative duties and focus on their vital research work.

Cure4CF also provided financial support for higher degree students to continue important work within the team once other funding sources had expired.

Emma Drew

Cure4CF expresses its sincere gratitude to Emma Drew who resigned as a Director at the June meeting of the Board. Emma's dedication has been invaluable in establishing the Cure4CF Foundation and in providing strong, focussed and professional leadership as inaugural Chairman. Emma's contribution towards the good governance of the organisation has provided a rock-solid framework for the ongoing growth of the Foundation as we seek to find a cure.

The Year Ahead

If 2011/12 was a year of a progress and capacity building then 2012/13 promises to be a year of excitement. It is in the next 12 months that we will see the benefits of the service agreement with the WCHN and a number of new fundraising initiatives. In the next twelve months, the Board of Cure4CF aims to establish a funding base to guarantee the ongoing work of the Adelaide Cystic Fibrosis Gene Therapy Research Group.

I would like to close by reiterating my sincere thanks to the many individuals and companies who have supported and been involved with Cure4CF throughout the year. To Dr David Parsons and the Adelaide Cystic Fibrosis Gene Therapy Research Group, it is our privilege to be able to support a focussed and innovative research project that holds such hope and potential. To all of the Cure4CF supporters and volunteers, it is thanks to you that we continue to make progress towards finding a cure for Cystic Fibrosis Airway Disease.

A handwritten signature in black ink, consisting of a stylized 'D' and 'C' followed by a long horizontal flourish.

David Coluccio
Chairman

Donor List

Personal

Shayne Bakewell	Lorraine Jerome
Jason Barnden	Gregg Johnson
Doreen Beadle	Linda Jones
Rachele Bridger	Celeste Kelly
Rosie Burn	Amanda Kenny
Peter Buss	Andrew Kenny
Robert Buss	Heather Kenny
Catherine Buss	Simon Kerr
Kayleen Charles	Sharon King
Leon Chiera	Andre Klavins
Karla Chou	Kerrie Lewicki
Jo Close	Maria Limberis
Patricia Cmielewski	Marisa Mallamo
Jasmine Cole	Jade Mason
Alex Conlon	Peter Masters
Sonia Corsini	Nick Mockford
David Coluccio	Cathy Murphy
Beryl Davis	Lanh Nguyen
Staxon de Mille	Brenton Oke
Lauren Dollery	Greg Oke
Martin Donnelley	James Oliver
David Edge	David Parsons
Wayne & Julia Edwards	Karen Plunkett
Philippa Edge	Andrew Potter
Graham Elliott	Corinne Reynolds
Kifa Elmassih	Danika Rohde
Leigh Fenn	Nick Rohde
Tim Finney	Peter Rohde
Robert Frances	Tegan Rowland
Gail Gill	Stephanie Saffi
Reanna Gray	William Saffi
Matt H	Brett Talbot
Brendan Hann	Cathy Treglown
Feda Hannouch	Joanne Turcie
Sue Hannouche	Mick Turner
Marg Henderson	Nikki Warner
Matt Henderson	Ashleigh Williams
Ursula Henderson	Brendan Williams
Vic Hilditch	David Williams
Amanda Hillier	Megan Williams
Deb Hosking	Monica Winter
Tonniel Houston	

Corporate & Community

Adelaide Airport Limited

Andersons Solicitors

Australian Executor Trustees Discretionary Charitable Trust

Ferrier Hodgson

Freer Parker

Independent Gaming Corporation

Messagemark

PPB Advisory

Variety – the children's charity

CURE4CF FOUNDATION LIMITED

ABN 71 136 956 137

DIRECTORS' REPORT

Your Board presents their report on the Cure4CF Foundation Limited for the financial year ended 30 June 2012.

Directors

The names of the each person who has been a director at any time during or since the end of the year are:

Ms Lorraine Caruso	
Mr David Coluccio	
Ms Emma Cecilia Drew	(Resigned 07/06/2012)
Mr Mark Evans	(Appointed 03/08/2011)
Ms Deb Hosking	(Appointed 03/08/2011)
Mr Gregg Robertson Johnson	
Mr Gregory Lancelot Oke	
Mr John William Winckel	

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Company Secretary

The following person held the position of entity secretary at the end of the financial year: Ms Lija Katrina Proske LLB/LP (Hons), B.App.Sc (SpPath), ACIS, was appointed Company Secretary on 26 May 2009.

Information on Company Officers

Mr David Coluccio

Qualifications

Experience

Chairman (non-executive)

BA, MA (Int.St.), MAICD

Appointed director on 26 May 2009

Appointed chairman on 2 December 2010

Ms Lorraine Caruso

Qualifications

Experience

Director

MBA, GAICD

Appointed director on 6 October 2010

Ms Emma Drew	Director
Qualifications	LLB (Hons), BEc., GDLP, GAICD B.A.
Experience	Appointed director on 26 May 2009 Chairman 26 May 2009 to 2 December 2010
Mr Mark Evans	Director
Experience	Appointed director on 3 August 2011
Ms Deb Hosking	Director
Experience	Appointed director on 3 August 2011
Mr Gregg Johnson	Director
Qualifications	CA, BCom., Ass.Dip. of Mech. Eng.
Experience	Appointed director on 7 April 2011
Mr Gregory Oke	Director
Qualifications	BApp.Sc., MBA, MCIPS
Experience	Appointed director on 26 May 2009
Ms Lija Proske	Company Secretary
Qualifications	LLB/LP (Hons), BApp.Sc (Sp.Path.), ACIS
Experience	Appointed company secretary on 26 May 2009
Mr John Winckel	Director
Qualifications	Dip.Ind.Chem
Experience	Appointed director on 26 May 2009

Meetings of Directors

The following table sets out the number of Director's meetings held during the financial year whilst the Directors were in office and the number of meetings attended by each Director:

Officer	Number of meetings eligible to attend	Number of meetings attended
Lorraine Caruso	6	6
David Coluccio	6	6
Emma Drew	6	6
Mark Evans	5	4
Deb Hosking	5	4
Gregg Johnson	6	6
Greg Oke	6	6
Lija Proske	6	5
John Winckel	6	5

Principal Activities

Cure4CF Foundation's principal activity during the financial year was the raising of funds to support raising awareness of cystic fibrosis airway disease and research into the development of a cure.

Operating Results

The profit of the entity amounted to: **\$127,107** (2011: \$61,397, 2010: \$119,712).

Dividends Paid or Recommended

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends or distributions has been made.

Significant Changes in State of Affairs

No significant change in the nature of those activities has occurred during that period.

After Balance Date Events

No matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the entity, the results of those operations, or the state of affairs of the entity in future financial years.

Future Developments

The entity expects to maintain the present status and level of operations and hence there are no likely developments in the entity's operations.

Environmental Issues

The entity's operations are not regulated by any significant environmental regulation under a law of the Commonwealth of a state or territory.

Options

No options over issued or unissued shares or interests in the entity were granted during or since the end of the financial year and there are no options outstanding at the date of this report.

No shares or interests were issued during or since the end of the financial year as a result of the exercise of an option over unissued shares or options.

Indemnifying Officers or Auditor

The Constitution of the entity provides for every officer of the entity to be indemnified against any liability incurred by that person as an officer of the entity, and for reasonable legal costs incurred in defending an action for a liability incurred by that person as an officer of the entity.

Insurance premiums have been paid to QBE Insurance for Associations Liability Insurance and Public Liability Insurance for the financial year.

No indemnities have been given during or since the end of the financial year, for any person who is or has been an auditor of the entity.

Proceedings on Behalf of the Entity

No person has applied for leave of Court to bring proceedings on behalf of the entity or intervene in any proceedings to which the entity is a party for the purpose of taking responsibility on behalf of the entity for all or any part of those proceedings.

The entity was not a party to any such proceedings during the year.

Auditor's Independence Declaration

The lead auditor's independence declaration as required under Section 307 of the *Corporations Act* 2001 for the year ended 30 June 2012 has been received and is attached to the directors' report.

Signed in accordance with a resolution of the Board of Directors.

A handwritten signature in dark ink, consisting of a stylized 'D' and 'C' followed by a long horizontal flourish.

DAVID COLUCCIO
Chairman

Dated this 31st day of AUGUST 2012

CURE4CF FOUNDATION LIMITED

ABN: 71 136 956 137

FINANCIAL REPORT

FOR THE YEAR ENDED 30 JUNE 2012

CURE4CF FOUNDATION LIMITED
ABN 71 136 956 137

STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2012

	2012	2011
	\$	\$
INCOME		
Events	\$0	\$0
Grants	\$109,800	\$15,420
Climbing Rose Wine	\$2,440	\$30,565
Personal Donations	\$7,966	\$10,382
Corporate Donations	\$11,332	\$15,471
Non-cash Donations	\$0	\$0
Member fees	\$28	\$28
Interest	\$896	\$692
Other	\$0	\$0
	<u>\$132,462</u>	<u>\$72,558</u>
LESS EXPENDITURE		
Events	\$0	\$0
Administration	\$34	\$1,596
Corporate fees & insurance	\$2,130	\$2,249
Grant Writing Services	\$215	\$3,354
Memberships	\$1,620	\$1,452
Web Design and Hosting	\$37	\$1,390
Other	\$1,276	\$1,120
	<u>\$5,312</u>	<u>\$11,161</u>
Profit before Income Tax	\$127,150	\$61,397
Income Tax Expense	-	-
PROFIT FOR THE YEAR	<u>\$127,150</u>	<u>\$61,397</u>
Other comprehensive expense		
Adelaide University Student Grant	\$2,400	\$3,390
Research Office Manager	\$8,261	\$13,650
WCH Research Account Transfer	\$0	\$10,250
WCH Research Equipment Funding	\$108,090	\$0
Total comprehensive income for the year	<u>\$8,399</u>	<u>\$34,107</u>
Profit attributable to members of the entity	<u>\$127,150</u>	<u>\$61,397</u>
Total comprehensive income attributable to members of the entity	<u>\$8,399</u>	<u>\$34,107</u>

The accompanying notes form part of these financial statements

CURE4CF FOUNDATION LIMITED
ABN 71 136 956 137

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2012

	2012	2011
	\$	\$
CURRENT ASSETS		
Cash & cash equivalents	\$86,738	\$77,836
Inventories	\$35,234	\$64,435
Other current assets	\$0	\$0
	<u>\$121,972</u>	<u>\$142,271</u>
NON-CURRENT ASSETS	\$0	\$0
Property, plant & equipment	\$0	\$0
Intangible assets	\$0	\$0
	<u>\$0</u>	<u>\$0</u>
TOTAL ASSETS	<u>\$121,972</u>	<u>\$142,271</u>
CURRENT LIABILITIES		
Trade and other payables	\$265	\$0
Other	\$0	\$0
	<u>\$265</u>	<u>\$0</u>
TOTAL LIABILITIES	<u>\$265</u>	<u>\$0</u>
NET ASSETS	<u>\$121,707</u>	<u>\$142,271</u>
EQUITY		
Retained earnings	\$121,707	\$142,271
TOTAL EQUITY	<u>\$121,707</u>	<u>\$142,271</u>

The accompanying notes form part of these financial statements

CURE4CF FOUNDATION LIMITED
ABN 71 136 956 137

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2012

	Retained Earnings	Total
	\$	\$
Balance as at 1 July 2010	\$138,729	\$138,729
Profit attributable to the entity	\$34,107	\$34,107
Sale of wine inventory	\$30,565	\$30,565
	<hr/>	<hr/>
Balance as at 30 June 2011	\$142,271	\$142,271
Profit attributable to the entity	\$8,399	\$8,399
GST adjustment	\$238	\$0
Sale of wine inventory	\$2,440	\$2,440
Write down of wine inventory	\$26,761	\$26,761
	<hr/>	<hr/>
Balance as at 30 June 2012	<u><u>\$121,707</u></u>	<u><u>\$121,469</u></u>

The accompanying notes form part of these financial statements

CURE4CF FOUNDATION LIMITED
ABN 71 136 956 137

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2012

	2012	2011
	\$	\$
CASH FLOW FROM OPERATING ACTIVITIES		
Receipts from customers	\$131,566	\$71,866
Payments to suppliers	\$4,809	\$11,161
Transfer of funds to:-	\$0	\$0
Adelaide University Student Grant	\$2,400	\$3,390
Research Office Manager	\$8,261	\$13,650
WCH Research Account	\$0	\$10,250
WCH Research Equipment Funding	\$108,090	\$0
Interest Received	\$896	\$692
Net cash generated from operating activities	<u>\$8,902</u>	<u>\$34,107</u>
 CASH FLOW FROM INVESTING ACTIVITIES		
Payment for property, plant & equipment	\$0	\$0
Payment for intangible asset	<u>\$0</u>	<u>\$0</u>
Net cash used in investing activities	<u>\$0</u>	<u>\$0</u>
 Net increase in cash held	\$8,902	\$34,107
Cash at beginning of financial year	\$77,836	\$43,729
 CASH AT END OF FINANCIAL YEAR	 <u><u>\$86,738</u></u>	 <u><u>\$77,836</u></u>

The accompanying notes form part of these financial statements

CURE4CF FOUNDATION LIMITED

ABN 71 136 956 137

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2012

The financial statements are for Cure4CF Foundation Limited as an individual entity, incorporated and domiciled in Australia. Cure4CF Limited is a not for profit company limited by guarantee.

Note 1: Statement of Significant Accounting Policies

Basis of Preparation

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users who are dependent on its general purpose financial reports. These financial statements are therefore special purpose financial statements that have been prepared in order to meet the requirements of the *Corporations Act 2001*.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the *Corporations Act 2001* and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with the previous period unless stated otherwise.

The financial statements have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes. The accounting policies that have been adopted in the preparation of this report are as follows:

Accounting Policies

a. Revenue

Donations and bequests are recognised as revenue when received.

Interest revenue is recognised as revenue when received.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

All revenue is stated exclusive of the amount of goods and services tax (GST).

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2011

Note 1: Statement of Significant Accounting Policies (cont'd)

b. Inventories

Inventories acquired at no cost, or for nominal consideration, are valued at net realisable value. At its June meeting, the Board resolved to discount the sale price of the wine inventory in order to promote further sales.

c. Property, Plant and Equipment

No property, plant or equipment was held at the end of the financial year.

d. Leases

No leases were held at the end of the financial year.

e. Financial Instruments

No financial instruments were held at the end of the financial year.

f. Impairment of Assets

At each reporting date, the entity reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the *Income Statement*.

Where the future economic benefits of the asset are not primarily dependent upon on the assets ability to generate net cash inflows and when the entity would, if deprived of the asset, replace its remaining future economic benefits, value in use is depreciated replacement cost of an asset.

Where it is not possible to estimate the recoverable amount of a class of asset, the entity estimates the recoverable amount of the cash-generating unit to which the class of assets belong.

g. Employee Benefits

There were no employees during the financial year.

h. Cash and cash equivalents

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2011

Note 1: Statement of Significant Accounting Policies (cont'd)

or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

i. Goods and Services Tax (GST)

Revenue and expenses are recognised inclusive of the amount of GST.

Cash flows are presented in the Cash flow Statement on a gross basis.

j. Income Tax

No provision for income tax has been raised as the entity is exempt from income tax under Div 50 of the *Income Tax Assessment Act 1997*.

k. Intangibles

No intangibles were held at the end of the financial year.

l. Provisions

Provisions are recognised when the entity has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of the reporting period.

m. Comparative Figures

Where required by Accounting Standards comparative figures have been adjusted to conform with changes in presentation for the current financial year.

n. Critical Accounting Estimates and Judgements

There are no critical accounting estimates and judgements required.

o. Economic Dependence

Cure4CF Foundation Limited is run by volunteers including the Board of Directors and other supporters. At the date of this report the Board of Directors has no reason to believe that the volunteers will not continue to support Cure4CF Foundation Limited.

p. Adoption of New and Revised Accounting Standards

During the current year the company adopted all of the new and revised Australian Accounting Standards and Interpretations applicable to its operations which became mandatory.

CURE4CF FOUNDATION LIMITED ABN 71 136 956 137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2011

Note 2: Entity Details

The registered office of the company is:

Cure4CF Foundation Limited

11 Andrew Avenue

Millswood SA 5034

The principal place of business is:

Cure4CF Foundation Limited

11 Andrew Avenue

Millswood SA 5034

Note 3: Members' Guarantee

The entity is incorporated under the *Corporations Act 2001* and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the company. At 30 June 2012 the number of members was 8.

CURE4CF FOUNDATION LIMITED

ABN 71 136 956 137

(A COMPANY LIMITED BY GUARANTEE)

DIRECTORS' DECLARATION

The directors of the company declare that:

- A. The financial statements and notes, as attached, are in accordance with the *Corporations Act 2001*:
 - i. comply with Accounting Standards and the Corporations Regulations 2001; and
 - ii. give a true and fair view of the financial position as at 30 June 2012 and the performance for the year ended on that date of the company.
- B. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors

A handwritten signature in dark ink, consisting of a stylized 'D' and 'C' followed by a long horizontal flourish.

DAVID COLUCCIO
Chairman

Dated this 31st day of AUGUST 2012

CURE4CF FOUNDATION LIMITED

ABN 71 136 956 137

**AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS
ACT 2001 TO THE DIRECTORS OF
CURE4CF FOUNDATION LIMITED**

I declare that to the best of my knowledge and belief, during the year ended 30 June 2012 there have been:-

- (i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
- (ii) no contraventions of any applicable code of professional conduct in relation to the audit.

Signed at Adelaide this *3rd* day of October 2012.



Consultant: Richard G Freer
Registered Company Auditor No 5211

C/- Freer Parker & Associates
40 Sturt Street
ADELAIDE SA 5000

INDEPENDENT AUDITOR'S REPORT

To the members of Cure4CF Foundation Limited

Report on the Financial Report

We have audited the accompanying financial report of Cure4CF Foundation Limited which comprises the statement of financial position as at 30 June 2012, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors Responsibility for the Financial Report.

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*, and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating of the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Cure4CF Foundation Limited, would be in the same terms if given to the directors as at the time of this auditor's report.

Basis for Qualified Opinion

It is not practicable for Cure4CF Foundation Limited to maintain an effective system of internal control over non-grant revenue until its initial entry in the accounting records and accordingly our audit in relation to such revenue was limited to the amounts recorded in the accounts.

Qualified Opinion

In our opinion except for the effects on the financial report of the matter described in the Basis for Qualified Opinion paragraph, the financial report of Cure4CF Foundation Limited is in accordance with the *Corporations Act 2001*, including:

- (i) giving a true and fair view of the company's financial position as at 30 June 2012 and its performance for the year ended on that date, and
- (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.



Richard G Freer
Consultant

Registered Company Auditor No 5211

Dated 3rd December 2012

C/- Freer Parker & Associates

40 Sturt Street ADELAIDE SA 5000